Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. XGEVA (denosumab)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

XGEVA (denosumab)

Medicine - Posted on May 24 2024
Active substance (DCI)
  • denosumab
history (3)
  • 5/15/24

    XGEVA (denosumab) - Oncology

    Summary of opinion Favourable opinion for reimbursement in the following indications: Prevention of skeletal related events ...
    CAV :
    54321
    icône flèche
  • 7/1/15

    XGEVA (denosumab), monoclonal antibody

    Minor improvement in the treatment of giant cell tumour of bone that is unresectable or where surgical resection is likely t...
    CAV :
    54321
    icône flèche
  • 4/11/12

    XGEVA (denosumab)

    Progrès thérapeutique mineur dans la prévention des complications osseuses de métastases issues d’un cancer du sein ou de la...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • M05BX04
Manufacturer
AMGEN S.A.S.
Presentation

XGEVA 120 mg, solution injectable (code CIS : 65243459)
1 flacon(s) en verre de 1,7 ml (CIP : 34009 217 253 8 4)
4 flacon(s) en verre de 1,7 ml (CIP : 34009 580 874 1 7)

XGEVA 120 mg, solution injectable en seringue préremplie
1 seringue préremplie en verre de 1 mL (CIP : 34009 302 899 0 7)

All our publications
    Bone and cartilage diseases Bone cancers Cancers - miscellaneous Drug therapy Paediatrics

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
VeQ5KNtB0YUaYSMD